Charles Schwab
ORGS

Charles Schwab’s Orgenesis Inc. Common Stock ORGS Stock Holding History

Charles Schwab’s Portfolio ORGS Stock Details ORGS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-4,842
Closed -$278K – 3556
2021
Q1 		$278K Hold
4,842
– – ﹤0.01% 3265
2020
Q4 		$218K Hold
4,842
– – ﹤0.01% 3247
2020
Q3 		$245K Hold
4,842
– – ﹤0.01% 3115
2020
Q2 		$295K Buy
+4,842
New +$293K ﹤0.01% 3054

Other funds holding ORGS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
E
Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return
TEE
Tibra Equities Europe London, United Kingdom $90.4M AUM 37.81% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

Charles Schwab's ORGS Position: Q2 2021 in Review

Charles Schwab sold out of Orgenesis Inc. Common Stock (ORGS) in Q2 2021, closing a stake of 4,842 shares — an estimated $278K sold.

Charles Schwab first reported a position in ORGS in Q2 2020 and held it in 4 quarters. The position peaked at $295K in Q2 2020. 33 funds tracked by Wall St. Rank hold ORGS as of Q2 2021.

  • Charles Schwab reported no remaining Orgenesis Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • Charles Schwab sold 4,842 Orgenesis Inc. Common Stock shares in Q2 2021, an estimated $278K.
  • Charles Schwab first reported a position in Orgenesis Inc. Common Stock in Q2 2020 and held it in 4 quarters.
  • Charles Schwab's Orgenesis Inc. Common Stock position peaked at $295K in Q2 2020.
  • 33 funds tracked by Wall St. Rank held Orgenesis Inc. Common Stock as of Q2 2021.

Based on Charles Schwab's 13F filing for Q2 2021, filed 16 Aug 2021.